Yuyan Pharmaceutical
誉颜制药
Yuyan Pharmaceutical (誉颜制药) is a biopharmaceutical company controlled by MingMed (因明生物), a Guangzhou-based biotech firm . Its flagship asset is YY001, a recombinant botulinum toxin type A injection developed through independent R&D with global intellectual property rights — notably the first recombinant botulinum toxin worldwide to enter regulatory review . The drug completed Phase I/II trials for moderate-to-severe glabellar lines by May 2022 , finished Phase III trials by late 2024 , and saw its marketing authorization application accepted by China's NMPA on December 31, 2024 . Gaorong Capital has tracked the company's progress across multiple portfolio updates .
AI-generated — may contain errors, please verify.
Coverage
Gaorong Report · 2025 | Innovative Drugs, Agri-Tech, AI Content Platforms Close Funding Rounds; Gaorong Earns Multiple Accolades
Innovation as the sail, hard work as the oar.
Rongbao | Power Semiconductor, Robotics Firms "Steer" Tech Upgrades, AI Applications Make Major Debuts
The Meaning of "Exploration"
Rongbao | Generative AI Powers Industries, Snack Chains Hit 10,000 Stores, Chip Tape-Out Success, Healthcare Goes Global
Innovation lights the path to growth.
Rongbao | Major Acquisition in Innovative Drugs; Laser Chips, Quantum Computing, and Global Payment Platform Secure New Funding
"Every step forward feels like a bloom."
New drug development, energy storage, computing, and semiconductors see breakthrough innovations: homegrown R&D, world-first technologies, and AI-driven advances
Constantly creating new possibilities.
Multiple cutting-edge technologies lead globally — 3D interaction, LiDAR, chips, and medical innovation continue apace | Rongbao · March
Keep learning and evolving through the long cycle of sustained innovation.
